Tisagenlecleucel

Status:
Do Not Prescribe (DNP), Red
Decision Date:
February 2019
 

Comments

RED

  •  NICE TA554 -  relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. (Decision date - Feb 2019)

DNP: 

  • NICE TA842 - treating follicular lymphoma after 2 or more therapies. Terminated appraisal. (Decision date - December 2022)
  • NICE TA933  Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. Terminated appraisal, replaces NICE TA567 (Decision - December 2023)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app